LUND, Sweden, Oct. 28, 2020 /PRNewswire/ -- Immunovia, a
diagnostic company that develops highly accurate blood tests for
the early detection of cancer and autoimmune diseases, today
announced that the company will host a webinar to introduce
incoming CEO, Patrik Dahlen on
Tuesday, November 3rd,
2020 at 9:00 CET. The webinar will
include a Q&A session with CEO, Patrik
Dahlen and Chairman, Carl Borrebaeck.
Immunovia previously announced the CEO transition on
August 26th, 2020 (link to
press release). Patrik Dahlen will
join Immunovia as the company's new CEO starting November 1, 2020. Mats
Grahn will assume a position on Immunovia's Board of
Directors.
Event Details:
Webinar Introducing New CEO, Patrik
Dahlen with Chairman, Carl Borrebaeck
Date: Tuesday, November 3rd,
2020
Time: 9:00 am CET
To join the webinar: Register for Webinar (link)
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently in the final validation phase. The company aims for a
sales start at the end of Q1 2021 with subsequent commercial
testing in Q2.
When validated, IMMray™ PanCan-d will be the first blood-based
test for early diagnosis of pancreatic cancer on the market, with a
potential to significantly improve patient survival and
outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
CONTACT:
Julie
Silbe
Director of Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46 7 93 486 277This information was brought to you by
Cision http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-to-host-webinar-introducing-new-ceo--patrik-dahlen,c3226694
The following files are available for download:
https://mb.cision.com/Main/13121/3226694/1326983.pdf
|
Release
|